Stock Events

Eterna Therapeutics 

$0.94
24
-$0.05-5.04% Today

Statistics

Day High
1
Day Low
0.86
52W High
2.63
52W Low
0.84
Volume
90,207
Avg. Volume
25,915
Mkt Cap
10.02M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

13
NOV
Earnings
 

Earnings

13NovExpected
Q3 2022
Q4 2022
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-2.49
-2
-1.52
-1.03
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ERNA. It's not an investment recommendation.
Alphabet
78260
GOOGL
Apple
68069
AAPL
Microsoft
63506
MSFT
Amazon
59244
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.06B
CRISPR Therapeutics is a leader in the development of gene-based therapies, directly competing with Eterna's focus on mRNA and gene editing technologies.
Editas Medicine
EDIT
Mkt Cap308.46M
Editas Medicine operates in the gene editing space, making it a direct competitor to Eterna Therapeutics in the development of gene therapy solutions.
Intellia Therapeutics
NTLA
Mkt Cap2.28B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing technology, competing in the same space as Eterna Therapeutics.
Beam Therapeutics
BEAM
Mkt Cap2.2B
Beam Therapeutics uses base editing, a form of gene editing, positioning it as a competitor in the gene therapy market alongside Eterna Therapeutics.
Sangamo Therapeutics
SGMO
Mkt Cap176.57M
Sangamo Therapeutics focuses on genomic medicine, including gene editing and gene therapy, competing with Eterna in the development of genetic treatments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap33.72B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, competing with Eterna's focus on mRNA therapies.
Ionis Pharmaceuticals
IONS
Mkt Cap6.97B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, making it a competitor in the RNA space with Eterna.
Biomarin Pharmaceutical
BMRN
Mkt Cap17.36B
BioMarin Pharmaceutical focuses on enzyme replacement therapies, which can be seen as complementary or competitive to gene therapies offered by Eterna.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.99B
Vertex Pharmaceuticals, with its focus on treating genetic diseases, competes in the broader market for genetic therapies that Eterna is also targeting.
Bluebird bio
BLUE
Mkt Cap108.22M
bluebird bio focuses on gene therapy for genetic diseases and cancer, directly competing with Eterna Therapeutics in the gene therapy space.

About

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Show more...
CEO
Employees
8
Country
US
ISIN
US1140822099

Listings

XNAS
US
ERNA